Patient-maintained propofol sedation for adult patients undergoing surgical or medical procedures: a scoping review of current evidence and technology

David W. Hewson*, Jonathan G. Hardman and Nigel M. Bedforth

Department of Anaesthesia and Critical Care Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK

*Corresponding author. E-mail: david.hewson@nottingham.ac.uk

Summary

Patient-maintained propofol sedation (PMPS) is the delivery of procedural propofol sedation by target-controlled infusion with the patient exerting an element of control over their target-site propofol concentration. This scoping review aims to establish the extent and nature of current knowledge regarding PMPS from both a clinical and technological perspective, thereby identifying knowledge gaps to guide future research. We searched MEDLINE, EMBASE, and OpenGrey databases, identifying 17 clinical studies for analysis. PMPS is described in the context of healthy volunteers and in orthopaedic, general surgical, dental, and endoscopic clinical settings. All studies used modifications to existing commercially-available infusion devices to achieve prototype systems capable of PMPS. The current literature precludes rigorous generalisable conclusions regarding the safety or comparative clinical effectiveness of PMPS, however cautious acknowledgement of efficacy in specific clinical settings is appropriate. Based on the existing literature, together with new standardised outcome reporting recommendations for sedation research and frameworks designed to assess novel health technologies research, we have made recommendations for future pharmacological, clinical, behavioural, and health economic research on PMPS. We conclude that high-quality experimental clinical trials with relevant comparator groups assessing the impact of PMPS on standardised patient-orientated outcome measures are urgently required.

Keywords: anxiolytic; conscious sedation; equipment design; hypnotics; propofol; sedatives; target-controlled infusion

Editor’s key points

- Patient control over analgesic or sedative agent administration may improve safety and patient satisfaction.
- Patient-maintained propofol sedation (PMPS) is a technique which combines target-controlled infusion and patient control technologies to provide a patient with some control over the depth of their sedation.
- The authors performed a scoping review to establish the extent and nature of current knowledge regarding PMPS.
- The current literature is limited, and high-quality clinical trials are needed to assess the impact of PMPS on standardised patient-orientated outcome measures.

The relief of anxiety and the provision of analgesia during awake surgical and medical procedures forms a large and increasing part of anaesthetic service delivery. The relief of perioperative anxiety and stress is one of the standardised endpoints for perioperative medicine research proposed by the Standardised Endpoints in Perioperative Medicine - Core Outcome Measures in Perioperative and Anaesthetic Care (StEP-COMPAC) Group and is an outcome measure of high priority for patients. Procedural sedation is commonly achieved using propofol delivered by target-controlled infusion (TCI), non-TCI ml h⁻¹ or μg kg⁻¹ min⁻¹ infusion, or intermittent i.v. bolus techniques. Such techniques are typically titrated to effect (i.e. sedation level) by healthcare professionals supervising the drug regimen. It is established clinical practice for patients to be given some element of titration control when using nitrous oxide, methoxyflurane, and i.v. opioid analgesia systems. No equivalent system exists to allow patients to exert...
direct control over their depth of sedation during propofol TCI sedation regimes. Such a technique can be termed patient-maintained propofol sedation (PMPS).

Given the importance of procedural anxiolysis to patients, the increase in the number of procedures being performed using sedation, and the varied approaches to propofol sedation undertaken worldwide (including instances of new propofol delivery systems being brought to and withdrawn from market) we have conducted a formal scoping review of the current literature on PMPS.

The aim of this scoping review is to establish the extent and nature of evidence regarding PMPS and to identify gaps in the existing literature. The objectives of this review are three-fold. First, to establish the populations and clinical settings in which PMPS has been studied. Second, to examine the range of pharmacokinetic models, sedation algorithms, and technologies that have delivered PMPS. Third, to explore studies of clinical efficacy or effectiveness and thereby recommend future research and technology development in this field.

Methods

This scoping review was performed according to the methodological principles described by Levac and colleagues and conforms to the 2018 Preferred Reporting Items for Systematic Review and Meta-analysis Extension for Scoping Reviews (PRISMA-ScR) reporting standards. Although the objectives of the review and the plan for its conduct were determined a priori, scoping review protocols are not accepted by the International Prospective Register of Systematic Reviews (PROSPERO) database, therefore the review was registered via ResearchRegistry.com (Reference: Researchregistry5389).

Definitions

There is no consensus definition of PMPS, however we propose to use the following definitions in this review. The delivery of propofol sedation by fixed bolus dose (measured in mg) with or without concurrent ml hr⁻¹ infusion, where the delivery of bolus doses is determined by the patient (typically using a handheld trigger), is called ‘patient-controlled propofol sedation’ (PCPS). Commercially available infusion devices (e.g. patient-controlled analgesia devices) can be re-purposed to deliver propofol sedation in this manner, although such modification typically requires formal regulatory authority approval since the device is then used beyond its intended use.

The delivery of propofol sedation by TCI, when the patient can influence their target-site concentration of propofol (in μg ml⁻¹) using a handheld trigger, is called patient-maintained propofol sedation (PMPS). The theoretical advantages of PMPS over PCPS are conferred by the use of target-controlling, which uses automated pharmacokinetic modelling to achieve rapid, reliable, and stable propofol compartment concentrations and therefore a stable and easily titratable depth of sedation.

Data sources and search for evidence

We searched MEDLINE and EMBASE databases from inception to May 1, 2020 via the Ovid® interface. The search terms ‘propofol’, ‘sedation’, ‘patient-led’, and ‘patient-maintained’ were applied with search truncation, wildcards, and Boolean operators as appropriate (see Supplementary online Appendix).
| Authors                  | Year | Title                                                                 | Country   | Study type | Study design | Participants (n) | Clinical setting                          |
|-------------------------|------|-----------------------------------------------------------------------|-----------|------------|--------------|------------------|---------------------------------------------|
| Irwin and colleagues    | 1997 | Patient-maintained propofol sedation: assessment of a target-controlled infusion system | Hong Kong | Efficacy   | Case series  | 36               | General and orthopaedic surgery            |
| Murdoch and Kenny       | 1999 | Patient-maintained propofol sedation as premedication in day-case surgery: assessment of a target-controlled system | UK        | Efficacy   | Case series  | 20               | Day case surgery                           |
| Murdoch and colleagues  | 2000 | Safety of patient-maintained propofol sedation using a target-controlled system in healthy volunteers | UK        | Efficacy   | Healthy volunteer study | 10 | N/A |
| Gillham and colleagues  | 2001 | Patient-maintained sedation for endoscopic retrograde cholangiopancreatography with a target-controlled infusion of propofol: a pilot study | UK        | Efficacy   | Case series  | 20               | Endoscopic retrograde cholangiopancreatography |
| Henderson and colleagues| 2002 | Patient-maintained propofol sedation: a follow-up safety study using a modified system in volunteers | UK        | Efficacy   | Healthy volunteer study | 20 | N/A |
| Leitch and colleagues   | 2003 | Patient-maintained sedation for oral surgery using a target-controlled infusion of propofol: a pilot study | UK        | Efficacy   | Case series  | 20               | Oral surgery                               |
| Rodrigo and colleagues  | 2003 | A randomised crossover comparison of patient-controlled sedation and patient-maintained sedation using propofol | Hong Kong | Effectiveness | Randomised crossover trial | 23 | Oral surgery |
| Campbell and colleagues | 2004 | Patient-maintained sedation for colonoscopy using a target-controlled infusion of propofol | UK        | Efficacy   | Case series  | 20               | Colonoscopy                                 |
| Authors                          | Year | Title                                                                 | Country | Study type | Study design                  | Participants (n) | Clinical setting |
|---------------------------------|------|------------------------------------------------------------------------|---------|------------|-------------------------------|------------------|------------------|
| Leitch and colleagues           | 2004 | A partially blinded RCT of patient-maintained propofol sedation and operator controlled midazolam sedation in third molar extractions | UK      | Effectiveness | RCT                           | 110              | Oral surgery     |
| Rodrigo and colleagues          | 2004 | Patient maintained propofol sedation for dental surgery                | Hong Kong | Efficacy | Case series                   | 50               | Oral surgery     |
| Anderson and colleagues         | 2005 | Effect-site controlled patient maintained propofol sedation: a volunteer safety study | UK      | Efficacy | Healthy volunteer study       | 20               | N/A              |
| Chapman and colleagues          | 2006 | Evaluation of a new effect-site controlled, patient-maintained propofol sedation system in dental patients | UK      | Efficacy | Case series                   | 40               | Oral surgery     |
| Stonell and colleagues          | 2006 | Effect-site targeted patient-controlled sedation with propofol: comparison with anaesthetist administration for colonoscopy | Australia | Effectiveness | RCT                           | 40               | Colonoscopy      |
| Allam and colleagues            | 2013 | Patient-maintained propofol sedation using reaction time monitoring: a volunteer safety study | UK      | Efficacy | Healthy volunteer study       | 20               | N/A              |
| O’Brien and colleagues          | 2013 | Reaction time-monitored patient-maintained propofol sedation: a pilot study in oral surgery patients | UK      | Efficacy | Case series                   | 20               | Oral surgery     |
| Hewson and colleagues           | 2019 | A prospective observational study of effect-site targeted, patient-maintained propofol sedation for lower limb orthopaedic surgery performed under spinal anaesthesia | UK      | Efficacy | Case series                   | 25               | Orthopaedic surgery |
| Hewson and colleagues           | 2019 | Anaesthetist-controlled vs patient-                                   | UK      | Effectiveness | Protocol for RCT          | 80               | Orthopaedic surgery |
I for details of the search strategy). ‘Patient-controlled’ was included in the search terms since there is variation in the nomenclature used by researchers to describe patient-led propofol sedation techniques. Tangential electronic exploration using citations to related texts was performed. To maximise search exposure, a supplemental search of grey literature was conducted using OpenGrey. Studies were limited to clinical trials reported in English. Animal studies were excluded, however opinion papers, case reports, and editorials were included if found. No existing reviews on this topic were identified in the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, National Institute for Health Research Health Technology Assessment Programme (NIHR HTA), NIHR i4i Programme, or the National Institute for Health and Care Excellence (NICE) websites.

All observational and experimental studies that addressed PAPS as defined above were considered for inclusion. All surgical and medical disciplines were considered including non-operative medical procedures such as colonoscopy and sedation in the emergency department or dental chair. We included studies with participants aged 18 yr or older either as healthy volunteers or patients. Studies were excluded if they described PCPS as defined above.

Screening and data extraction
All titles and abstracts identified by the initial search were screened for inclusion according to the selection criteria for detailed review. Discrepancies in data screening and extraction were resolved by consensus among the authors. Data on the following characteristics were extracted from included studies: titles, authors, publication year, study design, primary objectives, population characteristics and group allocations (including comparator group) if relevant, clinical setting, hardware used to deliver PAPS, pharmacokinetic model used for propofol delivery, compartment targeted during sedation, starting concentration of propofol targeted, incremental increase in propofol concentration triggered by patient request, lock-out time, maximum propofol concentration obtainable by patient during sedation, decrement in propofol concentration and decrement time if applicable, and minimum propofol concentration during sedation.

Results
A total of 4453 non-duplicate records were identified by the search, from which 76 full text articles were retrieved and evaluated (Fig. 1). Of the 76 identified texts, 17 describe PAPS. These articles, all of which are original research publications, are summarised in Table 1.

Population and clinical settings
PAPS has been examined in four healthy volunteer studies (a total of 70 participants), nine observational clinical studies (251 participants), and three prospective RCTs (150 participants). One RCT protocol, published by the authors of this review, comparing PAPS with anaesthetist-controlled propofol sedation in lower limb arthroplasty surgery was identified. The studies identified have taken place in the setting of general surgery, orthopaedic surgery, endoscopic retrograde cholangiopancreatography (ERCP), colonoscopy, and oral surgery.
Table 2: Pharmacokinetic models and sedation algorithms used in published studies. Terms are defined as follows: Starting concentration, the concentration of propofol at which participants commence the sedation regime; Increment concentration, the increase applied to the target-site concentration of propofol obtained by each participant handheld trigger activation; Lock-out time, the time after an increment in target-site concentration during which a subsequent handheld trigger activation will not cause a further increment; Maximum obtainable concentration, the ‘ceiling’ target-site concentration, above which the sedation will not increment regardless of handheld trigger activations; Decrement concentration, the target-site concentration reduction which is automatically applied in the event of no handheld trigger activations within the decrement time; Decrement time, the time which must expire with no handheld trigger activations before the decrement concentration is automatically applied; Minimum concentration, the target-site concentration below which the sedation will not decrement during the sedation period.

| Authors                      | Year Propofol model | Target-site | Starting concentration (µg ml⁻¹) | Increment concentration (µg ml⁻¹) | Lock-out (sec) | Maximum obtainable concentration (µg ml⁻¹) | Decrement concentration (µg ml⁻¹) | Decrement time (s) | Minimum concentration (µg ml⁻¹) |
|------------------------------|---------------------|-------------|----------------------------------|----------------------------------|---------------|-------------------------------------------|----------------------------------|-------------------|----------------------------------|
| Irwin and colleagues         | 1997 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 3.0           | 0.2                                       | Variable 0.2                   |                   |                                  |
| Murdoch and Kenny            | 1999 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 3.0           | Unspecified 360 0.2                       | 360 0.2                         |                   |                                  |
| Murdoch and colleagues       | 2000 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 3.0           | Unspecified 360 0.2                       | 360 0.2                         |                   |                                  |
| Gillham and colleagues       | 2001 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 3.0           | 0.2                                       | 360 Unspecified                |                   |                                  |
| Henderson and colleagues     | 2002 Marsh Plasma   | 0.5         | 0.1                              | 240                              | 3.0           | Unspecified Unspecified Unspecified       | Unspecified Unspecified        |                   |                                  |
| Leitch and colleagues        | 2003 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 3.0           | 0.2                                       | 360 Unspecified                |                   |                                  |
| Rodrigo and colleagues       | 2003 Marsh Plasma   | 1.4         | 0.2                              | 120                              | 3.0           | 0.2                                       | Variable 0.2                   |                   |                                  |
| Campbell and colleagues      | 2004 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 4.5           | Unspecified Unspecified Unspecified       | Unspecified Unspecified        |                   |                                  |
| Leitch and colleagues        | 2004 Marsh Plasma   | 1.0         | 0.2                              | 120                              | 3.0           | Unspecified Unspecified Unspecified       | 360 Unspecified                |                   |                                  |
| Rodrigo and colleagues       | 2004 Marsh Plasma   | 1.4         | 0.2                              | 120                              | 3.0           | 0.2                                       | Variable 0.2                   |                   |                                  |
| Anderson and colleagues      | 2005 Marsh Effect-site | 1.0     | 0.2                              | Variable No maximum              | 0.2           | 360 Unspecified                            |                                 |                   |                                  |
| Chapman and colleagues       | 2006 Marsh Effect-site | 1.0     | 0.2                              | Variable No maximum              | No decrement  N/A  Unspecified     |                                 |                                 |                   |                                  |
| Stonell and colleagues       | 2006 Schnider Effect-site | 0.8    | 0.1                              | 180                              | No maximum    | 0.1                                       | 300 Unspecified                |                   |                                  |
| Alam and colleagues          | 2013 Marsh Effect-site | 1.0     | 0.2                              | Variable 3.0                     | Variable      | Variable Unspecified                      |                                 |                   |                                  |
| O’Brien and colleagues       | 2013 Marsh Effect-site | 1.0     | 0.2                              | Variable 3.0                     | No decrement  N/A  Unspecified     |                                 |                                 |                   |                                  |
| Hewson and colleagues        | 2019 Schnider Effect-site | 0.5    | 0.2                              | Variable 2.0                     | 0.1           | 360 0.5                                   |                                 |                   |                                  |
| Hewson and colleagues        | 2019 Schnider Effect-site | 0.5    | 0.2                              | 120                              | 2.0           | 0.1                                       | 900 0.5                         |                   |                                  |
conditions) and effectiveness (the comparative operation of the technique in a pragmatic clinical environment) are fundamental to the potential adoption of new medical techniques and technologies and as such the literature can be broadly divided into examinations of efficacy8–13,15,18,19,21–23 and comparative effectiveness14,16,20 with the acknowledgement that the two concepts are a continuum rather than a dichotomy in clinical research.27

All four healthy volunteer studies have assessed efficacy and safety by instructing participants to render themselves unconscious using the PMPS handheld trigger. In addition to direct modifications of the parameters of the sedation algorithm (as defined in Table 2), the authors of these studies suggest the risk of over-sedation can be reduced by the use of a handheld trigger which must be pressed twice within 1 s to successfully increment the target-site concentration,10 the direct supervision of PMPS by an anaesthetist,2 and the integration of a user-reaction time monitor.21

Efficacy has been further assessed in nine case-series. While these studies universally describe high patient ‘satisfaction’ or ‘willingness to repeat the procedure’ after the PMPS technique,8,11,13,15 none reported outcome measures relating to patient comfort to a standard which would facilitate generalisable analysis or conclusions.29 These studies additionally demonstrate that under- and over-sedation can occur using PMPS if the sedative properties of propofol and the sedation algorithm used are not matched to the particular clinical setting. For example, in the case series of PMPS used for ERCP, Gillham and colleagues11 describe three of their 20 patients being insufficiently sedated to tolerate the procedure. Patients undergoing painful procedures, such as ERCP, are likely to benefit from an analgesic component to their sedation regime which propofol alone cannot provide. Although several studies present data demonstrating stability of physiological parameters (participant HR, arterial oxygen saturations, BP) during the sedation period,8,16,18 data arising from small and heterogeneous observational trials (251 participants in total) on the safety of anaesthetic techniques must be interpreted carefully, since much larger samples are required to conclusively demonstrate safety in specific clinical settings.29

Pharmacokinetic models, sedation algorithms, and technologies

With the exception of two studies that used Schnider modelling,20,23 all completed studies used the Marsh model of propofol TCI. All studies published before 2005 were conducted using plasma-compartment targeting, whereas those studies published after 2005 all used effect-site targeting. Until more recently published propofol TCI models, such as the Eleveld model,25 become available on commercial infusion devices or via open source software6,16 it is likely that Marsh or Schnider modelling will remain standard for PMPS research techniques.

The sedation algorithms used in individual studies are defined and summarised in Table 2. There was wide variation in the published starting concentrations of propofol (0.5–1.4 μg ml⁻¹), increment concentrations (0.1–0.2 μg ml⁻¹), lock-out times (120–240 s), maximum obtainable concentrations (2.0–4.5 μg ml⁻¹), decrement concentrations (0.1–0.2 μg ml⁻¹), decrement times (300–900 s), and minimum obtainable concentrations (0–0.5 μg ml⁻¹).

In the absence of a commercially available infusion device capable of PMPS, researchers report a variety of infusion devices modified by serial-port connection to bespoke software in order to deliver PMPS. The Omheda 9000 device (ROC Healthcare, Manchester, UK),8 Graseby 3400 (Smiths Medical Ltd, Ashford, UK),8,15–18 Graseby 3500 (Smiths Medical Ltd, Ashford, UK),21,22 Asena GH (BD Ltd, Wokingham, UK),20 Alaris FK (BD Ltd, Wokingham, UK),23 and the Perfusor fm (B. Braun Medical, Melsungen, Germany)24 have all been modified in this manner. One study did not specify the technology by which their PMPS algorithm was delivered.19

Clinical efficacy of PMPS

The concepts of efficacy (the operation of the sedation technique under ideal conditions, usually in closely supervised

Comparative clinical effectiveness of PMPS

There are three published randomised trials of PMPS addressing comparative effectiveness15,17,20. Two trials compared PMPS with control groups that could be described as ‘standard care’: physician-delivered midazolam sedation in Leitch and colleagues16 and anaesthetist-controlled propofol sedation in Stonell and colleagues.20 In the third trial, Rodrigo and colleagues14 compared PMPS with a PCPS technique using a crossover design.

Leitch and colleagues16 randomised 110 participants to PMPS or midazolam sedation for oral surgery performed under local anaesthetic infiltration with joint primary outcome measures of minimum arterial oxygen saturations during sedation and time until discharge from the theatre suite. PMPS offered superior reduction in mean (standard deviation [SD]) VAS-rated intraoperative anxiety compared with physician-controlled midazolam (21.21 vs 11.18 mm; P=0.010). Depth of sedation, as reported by the unblinded operating surgeon, was less in the PMPS group, and so the authors discuss the possibility that PMPS provides superior intraoperative anxiolysis, but less deep sedation, compared with midazolam under physician control. Recall of surgical events was similar

| Pharmacokinetic models, sedation algorithms, and technologies |
|---------------------------------------------------------------|
| With the exception of two studies that used Schnider modelling,20,23 all completed studies used the Marsh model of propofol TCI. All studies published before 2005 were conducted using plasma-compartment targeting, whereas those studies published after 2005 all used effect-site targeting. Until more recently published propofol TCI models, such as the Eleveld model,25 become available on commercial infusion devices or via open source software6,16 it is likely that Marsh or Schnider modelling will remain standard for PMPS research techniques. |
| The sedation algorithms used in individual studies are defined and summarised in Table 2. There was wide variation in the published starting concentrations of propofol (0.5–1.4 μg ml⁻¹), increment concentrations (0.1–0.2 μg ml⁻¹), lock-out times (120–240 s), maximum obtainable concentrations (2.0–4.5 μg ml⁻¹), decrement concentrations (0.1–0.2 μg ml⁻¹), decrement times (300–900 s), and minimum obtainable concentrations (0–0.5 μg ml⁻¹). |
| In the absence of a commercially available infusion device capable of PMPS, researchers report a variety of infusion devices modified by serial-port connection to bespoke software in order to deliver PMPS. The Omheda 9000 device (ROC Healthcare, Manchester, UK),8 Graseby 3400 (Smiths Medical Ltd, Ashford, UK),8,15–18 Graseby 3500 (Smiths Medical Ltd, Ashford, UK),21,22 Asena GH (BD Ltd, Wokingham, UK),20 Alaris FK (BD Ltd, Wokingham, UK),23 and the Perfusor fm (B. Braun Medical, Melsungen, Germany)24 have all been modified in this manner. One study did not specify the technology by which their PMPS algorithm was delivered.19 |

| Comparative clinical effectiveness of PMPS |
|------------------------------------------|
| There are three published randomised trials of PMPS addressing comparative effectiveness15,17,20. Two trials compared PMPS with control groups that could be described as ‘standard care’: physician-delivered midazolam sedation in Leitch and colleagues16 and anaesthetist-controlled propofol sedation in Stonell and colleagues.20 In the third trial, Rodrigo and colleagues14 compared PMPS with a PCPS technique using a crossover design. |
| Leitch and colleagues16 randomised 110 participants to PMPS or midazolam sedation for oral surgery performed under local anaesthetic infiltration with joint primary outcome measures of minimum arterial oxygen saturations during sedation and time until discharge from the theatre suite. PMPS offered superior reduction in mean (standard deviation [SD]) VAS-rated intraoperative anxiety compared with physician-controlled midazolam (21.21 vs 11.18 mm; P=0.010). Depth of sedation, as reported by the unblinded operating surgeon, was less in the PMPS group, and so the authors discuss the possibility that PMPS provides superior intraoperative anxiolysis, but less deep sedation, compared with midazolam under physician control. Recall of surgical events was similar |
PMPS, patient-maintained propofol sedation; TCI, target-controlled infusion.

### Table 3 Research suggestions for patient-maintained propofol sedation.

| Topic                             | Suggested research strategy                                      |
|-----------------------------------|------------------------------------------------------------------|
| Health economic evaluation        | Cost-consequence, cost-utility analysis, or both                 |
| Health system efficiency          | Healthcare resource use analysis                                 |
| Clinical safety and effectiveness  | High-quality experimental trials with relevant comparator group(s) assessing the impact of PMPS on standardised patient-oriented outcome measures.33,34 |
| User credibility, acceptability,  | Assessments of technology and technique to supervising health    |
| and engagement                    | professionals, patients, and commissioners of health services    |
| Behavioural assessment            | Qualitative psychological evaluations of patient and healthcare professional experience of PMPS |
| Pharmacological validation studies| Pharmacodynamic and pharmacokinetic predictive performance of specific propofol TCI models when adopted for PMPS |

between groups, but PMPS patients had a shorter mean (sd) time to readiness for discharge compared with the patients who had received midazolam (18 [5.5] vs 25 [9.0] min; P=0.001). The mean (sd) lowest arterial oxygen saturation was lower in the midazolam group than in the PMPS group (97.0 [2.0] vs 97.8 [1.8] %; P=0.026), however there is no clinical significance to this difference.

In 2006, Stonell and colleagues20 published an RCT of Schnider effect-site targeted PMPS vs anaesthetist-controlled propofol sedation by intermittent bolus in 40 patients undergoing colonoscopy. There was no difference in primary outcome measure, procedural satisfaction measured on VAS, between groups (91 vs 90 mm; P=0.779). The PMPS group was less sedated than the control group, with higher mean (sd) bispectral index (88 [9] vs 78 [11]; P=0.011) and median (inter-quartile range [range]) Observer Assessment of Alertness/Sedation scores 4 (4–5 [3–5]) vs 3 (2–4 [1–5]).

A single randomised trial has been conducted comparing PMPS with PCPS.31 The trial recruited 23 patients undergoing bilateral oral surgery scheduled as two separate surgical procedures. On their first operative visit patients were randomly assigned to either plasma-compartment targeted Marsh model PMPS or to a PCPS system delivering propofol 18 mg with a 60 s lock-out. On the second operative visit, participants received the alternate allocation. The authors conclude that PMPS and PCPS result in similar mean (sd) total propofol doses during the sedation period (84.3 [38.6] vs 93.7 [20.4] µg kg⁻¹ min⁻¹; P=0.13) but PMPS was preferred by more patients compared with PCPS (15 vs 7; P=0.02).

Risk of bias assessment

Although scoping reviews do not always include an assessment of internal validity, it was deemed appropriate to do so in the context of the available literature on PMPS. Each trial was assessed using predefined criteria specified in the Cochrane Risk of Bias Tool for Randomised Controlled Trials29 and a summary is presented in Figure 2. The overall quality of the trials was low with inadequate descriptions of methods undertaken to reduce selection, attrition, and reporting bias in two of the three trials.14,16 Effective blinding of participants, surgeons, anaesthetists, and outcome assessors is a complex area in sedation trials. There may be justifiable reasons for not blinding participants since some of the anxiolytic effect of PMPS may result from the psychological empowerment they obtain from knowing they can control their sedation using a button. To blind participants (with sham buttons or similar) may therefore alter the impact of the intervention itself. The extent to which psychological empowerment facilitates anxiolysis during PMPS should be a topic of future research.

### Discussion

This scoping review has identified the extent of research undertaken on PMPS. Sixteen healthy volunteer, observational, or RCTs of PMPS were published between 1997 and 2020. One RCT protocol has been published. The completed studies involved a total of 471 participants. We identified assessments of PMPS in medical and surgical procedural settings, using both Marsh and Schnider modelling and using a wide range of sedation algorithms. All PMPS research to date has been conducted using research-group specific software modifications to existing commercially available infusion devices, repurposing these devices for PMPS delivery.

The body of literature assessing PMPS is markedly smaller than that available for PCPS, where a recent systematic review conducted meta-analyses on clinical trial data for 1103 participants.31 The ease with which PCPS can be administered (requiring no software or hardware modification to TCI infusion devices) may explain this difference. It is our contention, however, that the pharmacokinetic advantages of TCI propofol delivery (established from its widespread use as an anaesthetist-controlled sedative and agent of general anaesthesia) are such that PMPS, rather than PCPS, should be the focus of future technological development and sedation research.

### Methodological considerations

Heterogeneity in clinical trial outcome measurement and reporting causes well known difficulties in evidence synthesis, and initiatives to encourage standardisation of outcomes measures32 are comparatively new in the context of the available literature on PMPS. Studies identified in this review have typically used non-standardised measures of depth of sedation, physiological manifestations of over-sedation, patient satisfaction or anxiety, time to recovery from sedation, or propofol consumption, or all of these end-points, in their outcome reporting. There is, however, an emerging consensus led by groups such as the Sedation Consortium on Endpoints and Procedures for Treatment, Education and Research (SCEPTER) that procedural sedation should be evaluated using...
consistent domains such as safety, effectiveness, patient-centeredness, and efficiency. Furthermore, these domains should be evaluated using recommended instruments to provide consistency and facilitate subsequent meta-analysis. The International Committee for the Advancement of Procedural Sedation has developed the Tracking and Reporting Outcomes Of Procedural Sedation (TROOPS) framework to promote consistency and standardised data collection for sedation research and quality improvement.

Technological context
From a technological perspective we can infer from this scoping review that PMPS is in the well-known biotechnology ‘valley of death’, where novel technologies with early proof-of-concept prototype success delivered by individual research groups are not subsequently exploited by product development into healthcare technologies ready for commercialisation and market adoption. There is a circularity in the relationship between the technology required to deliver PMPS and the sedation method itself. The absence of an accessible infusion device capable of PMPS is a barrier preventing researchers from conducting rigorous clinical evaluations of the sedation technique, but the paucity of evidence to support clinical effectiveness likely deters potential investors from bringing the technology to market and making it available for research. Although novel technology development opportunities exist (e.g. in the role of fuzzy logic/machine learning applied to PMPS or the adoption of new propofol TCI models for the PMPS technique), a basic commercially available infusion device capable of PMPS and approved by relevant regulatory authorities will be needed to conclusively demonstrate clinical effectiveness.

Recommendations for future research
Based on the evidence presented in this review, we have adapted the 2019 UK NICE Evidence Standards Framework for Digital Health Technologies to provide future research suggestions for PMPS. These are shown in Table 3.

Review limitations
Although the conduct and reporting of our work conforms to current best-practice in scoping review methodology, this approach to evidence synthesis is relatively new and our work is subject to several limitations. We used broad search criteria to identify all evidence relating to PMPS, but deliberately did not aim to critically appraise or systematically synthesise all results. Generalisable data-driven conclusions on the safety, efficacy, or effectiveness of PMPS (as would typically be found in systematic reviews) cannot be drawn from our work. Given the variety of nomenclature used to describe patient-led propofol sedation it is possible we have omitted sources of evidence which would have usefully contributed to our understanding of the current knowledge base of PMPS. Furthermore, our review is likely to have overlooked non-publicly accessible sources of information on PMPS, such as unpublished data (which may be commercially sensitive), patent applications or granted patents since a formal patent search was not undertaken.

Conclusions
Research evaluating the role of PMPS has been conducted on healthy volunteers and in observational and experimental clinical trials with participants from a range of medical and surgical settings. Results from an ongoing prospective RCT are awaited. Although the heterogeneity and reporting quality of completed studies precludes meta-analysis to determine safety or comparative clinical effectiveness, cautious acknowledgement that PMPS appears to provide efficacious procedural sedation in adult patients is appropriate. Both SCEPTER and TROOPS recommendations on the evaluation of sedation techniques and NICE guidelines in the assessment of healthcare technologies should be used by researchers and device manufacturers to determine how PMPS should be implemented in clinical practice.

Authors’ contributions
Study design, planning, conduct, writing, and revision of manuscript: all authors.

Declarations of interest
DWH and NMB have received unrestricted grants from Braun Medical AG to support departmental clinical research. JGH is the associate editor-in-chief of the British Journal of Anaesthesia and accepts fees for advising in civil, criminal, and coronial medicolegal cases.

Funding
National Institute for Health Research (UK); Invention for Innovation Programme (II-LA-0716-20002).

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.bja.2020.07.053.

References
1. Sury MRJ, Palmer JHMG, Cook TM, Pandit JJ. The state of UK anaesthesia: a survey of National Health Service activity in 2013. Br J Anaesth 2014; 113: 575–84
2. Myles PS, Grocott MPW, Boney O, et al. Standardizing end points in perioperative trials: towards a core and extended outcome set. Br J Anaesth 2016; 116: 586–9
3. Goudra B, Singh PM. Failure of Sedays: destiny or poor design? Anesth Analg 2017; 124: 686–8
4. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci 2010; 5: 69
5. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018; 169: 467–73
6. Wong SSL, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006; 94: 41–7
7. System for information on grey literature in Europe: OpenGrey. Available from: http://www.opengrey.eu. [Accessed 11 February 2020]
8. Irwin MG, Thompson N, Kenny GNC. Patient-maintained propofol sedation. Anaesthesia 1997; 52: 525–30
9. Murdoch JA, Kenny GNC. Patient-maintained propofol sedation as premedication in day-case surgery: assessment of a target-controlled system. Br J Anaesth 1999; 82: 429–31
10. Murdoch JAC, Grant SA, Kenny GNC. Safety of patient-maintained propofol sedation using a target-controlled system in healthy volunteers. Br J Anaesth 2000; 85: 299–316
11. Gillham MJ, Hutchinson RC, Carter R, Kenny GNC. Patient-maintained sedation for ERCP with a target-controlled infusion of propofol: a pilot study. Gastrointest Endosc 2001; 54: 14–7
12. Henderson F, Absalom AR, Kenny GNC. Patient-maintained propofol sedation: a follow-up safety study using a modified system in volunteers. Anaesthesia 2002; 57: 387–90
13. Leitch J, Sutcliffe N, Kenny GNC. Patient-maintained sedation for oral surgery using a target-controlled infusion of propofol – a pilot study. Br Dent J 2003; 194: 43–5
14. Rodrigo MRC, Irwin MG, Tong CKA, Yan SY. A randomised crossover comparison of patient-controlled sedation and patient-maintained sedation using propofol. Anaesthesia 2003; 58: 333–8
15. Campbell L, Imrie G, Doherty P, et al. Patient-maintained sedation for colonoscopy using a target controlled infusion of propofol. Anaesthesia 2004; 59: 127–32
16. Leitch JA, Anderson K, Gambhir S, et al. A partially blinded randomised controlled trial of patient-maintained propofol sedation and operator controlled midazolam sedation in third molar extractions. Anaesthesia 2004; 59: 853–60
17. Rodrigo MRC, Irwin MG, Yan SW, To PCY. Patient-maintained propofol sedation for dental surgery. Int Dent J 2004; 54: 177–81
18. Anderson KJ, Leitch JA, Green JS, Kenny GNC. Effect-site controlled patient maintained propofol sedation: a volunteer safety study. Anaesthesia 2005; 60: 235–8
19. Chapman RM, Anderson K, Green J, Leitch JA, Gambhir S, Kenny GNC. Evaluation of a new effect-site controlled, patient-maintained sedation system in dental patients. Anaesthesia 2006; 61: 345–9
20. Stonell CA, Leslie K, Absalom AR. Effect-site targeted patient-controlled sedation with propofol: comparison with anaesthetist administration for colonoscopy. Anaesthesia 2006; 61: 240–7
21. Allam S, Anderson KJ, O’Brien C, et al. Patient-maintained propofol sedation using reaction time monitoring: a volunteer safety study. Anaesthesia 2013; 68: 154–8
22. O’Brien C, Urquhart CS, Allam S, et al. Reaction time-monitored patient-maintained propofol sedation: a pilot study in oral surgery patients. Anaesthesia 2013; 68: 760–4
23. Hewson DW, Shanmuganathan S, Chikkaabaih V, Buchanan H, Hardman JG, Bedforth NM. A prospective observational study of effect-site targeted, patient-maintained propofol sedation for lower limb orthopaedic surgery performed under spinal anaesthesia. Eur J Anaesthesiol 2019; 36: 381–3
24. Hewson DW, Worcester F, Sprinks J, et al. Anaesthetist-controlled versus patient-maintained effect-site targeted propofol sedation during elective primary lower-limb arthroplasty performed under spinal anaesthesia (AC想法—CEPTS): study protocol for a parallel-group randomised comparison trial. Trials 2019; 20: 129
25. Eleveld DJ, Colin P, Absalom AR, Struys MMR. Pharmacokinetic–pharmacodynamic model for propofol for broad application in anaesthesia and sedation. Br J Anaesth 2018; 120: 942–59
26. Open TCI Initiative. Available from: http://opentci.org. [Accessed 11 February 2020]
27. Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014; 5: e45
28. Myles PS, Boney O, Botti M, et al. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (STEP) initiative: patient comfort. Br J Anaesth 2018; 120: 705–11
29. Pandit JJ. If it hasn’t failed, does it work? On ‘the worst we can expect’ from observational trial results, with reference to airway management devices. Anaesthesia 2012; 67: 578–83
30. Higgins JPT, Altman DG, Getzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
31. Kreienbühl L, Elia N, Pfeil-Beun E, Walder B, Tramèr MR. Patient-controlled versus clinician-controlled sedation with propofol. Anesth Analg 2018; 127: 873–80
32. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials 2017; 18: 280
33. Williams MR, Ward DS, Carlson D, et al. Evaluating patient-centered outcomes in clinical trials of procedural sedation, part 1 efficacy: sedation consortium on endpoints and procedures for treatment, education, and research recommendations. Anesth Analg 2017; 124: 821–30
34. Ward DS, Williams MR, Berkenbosch JW, et al. Evaluating patient-centered outcomes in clinical trials of procedural sedation, part 2 safety: sedation consortium on endpoints and procedures for treatment, education, and research recommendations. Anesth Analg 2018; 127: 1146–54
35. Roback MG, Green SM, Andolfatto G, Leroy PL, Mason KP. Tracking and reporting outcomes of procedural sedation (TROOPS): standardized quality improvement and research tools from the International Committee for the Advancement of Procedural sedation. Br J Anaesth 2018; 120: 164–72
36. National Institute for Health and Care Excellence. Evidence standards framework for digital health technologies, London 2019

Handling editor: Tony Absalom